Evotec Lowers Full-Year Outlook Amid Weaker Q2 Results

Evotec AG (NASDAQ:EVO) reported weaker-than-expected preliminary results for Q2 and H1 of 2026, leading to a downward revision in its full-year outlook. The company cited delayed strategic partnership revenue, slower commercial activity conversion into revenue, and foreign exchange headwinds as key factors.

By MarketBeat Tue, July 14, 2026 at 4:03 PM GMT+3 7 min read · Yahoo Finance · July 14, 2026, 13:03 UTC

Evotec Lowers Full-Year Outlook Amid Weaker Q2 Results

Tickers: $EVO $EVT

Topics: drug discovery financial performance pharmaceuticals

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC
SpaceX Shares Rise Following Nvidia CEO Jensen Huang Resignation Motley Fool · November 12, 2026, 16:34 UTC
tZERO Receives CFTC Approval for Derivatives Exchange and Clearing Operations PR Newswire · November 12, 2026, 16:36 UTC
enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade Seeking Alpha · November 12, 2026, 16:33 UTC
Former Nvidia CEO Jensen Huang to Testify Before Congress Regarding Export Controls and Security Concerns TechCrunch · November 12, 2026, 16:36 UTC
Nobu Hospitality and Infracorp Partner to Develop Luxury Destination in Bahrain PR Newswire · November 12, 2026, 16:34 UTC
Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC